Publications by authors named "Cecilia Boz"
Article Synopsis
- Galectin-3 (Gal-3) is linked to fibrosis in chronic lung injury, but its effects on acute lung injury (ALI) are not well understood, highlighting the need for new treatments.
- The study investigates GB0139, a Gal-3 inhibitor in clinical trials for idiopathic pulmonary fibrosis, to see if it can protect against ALI and examines its pharmacokinetics in mice.
- Results indicate that GB0139 reduces inflammation by decreasing neutrophil and macrophage activity and inhibits pro-inflammatory gene expression, suggesting it could be a viable treatment for ALI.
High circulating galectin-3 is associated with poor outcomes in patients with coronavirus disease (COVID-19). We hypothesized that GB0139, a potent inhaled thiodigalactoside galectin-3 inhibitor with antiinflammatory and antifibrotic actions, would be safely and effectively delivered in COVID-19 pneumonitis. Primary outcomes were safety and tolerability of inhaled GB0139 as an add-on therapy for patients hospitalized with COVID-19 pneumonitis.
View Article and Find Full Text PDFBackground: Many repurposed drugs have progressed rapidly to Phase 2 and 3 trials in COVID19 without characterisation of Pharmacokinetics /Pharmacodynamics including safety data. One such drug is nafamostat mesylate.
Methods: We present the findings of a phase Ib/IIa open label, platform randomised controlled trial of intravenous nafamostat in hospitalised patients with confirmed COVID-19 pneumonitis.